SOLO-1 trial evaluated Lynparza as a maintenance treatment for patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer. The results show that 60 percent of the patients lives with the disease without getting worse at 36 months compared to 27 percent in the placebo group.
SOLO-1 trial could change the way patiens are treated. Not only it demonstrates the importance of identifying a patient’s BRCA mutation status at the time of diagnosis, but it also opens up new possibilities to test drugs combinations, for example in immuno-oncology settings.
OvaCure is delighted to learn about this important milestone presented by AstraZeneca and Merck & Co. at the Presidential Symposium at the European Society for Medical Oncology (ESMO) 2018 Congress and wishes good luck with future research developments.
Learn more: https://www.biospace.com/article/esmo-2018-60-percent-of-ovarian-cancer-patients-receiving-lymparza-were-progression-free-at-3-years/